Retatrutide (LY3437943) is a first-in-class triple-receptor agonist peptide developed by Eli Lilly that simultaneously activates three metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon
15.2.18 TEVA PHARMACEUTICAL INDUSTRIES LTD
Wu D, He H, Chen J, Yao S, Xie H, Jiang W, et al
Weeks 14: You may not see visible changes in skin tone yet
Hybholt M
PlexusDx Precision Peptide Genetic Test analyzes 150+ insights across 49 peptides and 14 pathways, including GIPR, FTO, and MC4R variants that correlate with medication response and metabolic rate